| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homosexuality, Male | 188 | 2021 | 438 | 44.640 |
Why?
|
| Bisexuality | 122 | 2020 | 202 | 34.430 |
Why?
|
| Sexual Behavior | 116 | 2023 | 587 | 20.090 |
Why?
|
| HIV Infections | 164 | 2021 | 2207 | 19.110 |
Why?
|
| Sexual Partners | 85 | 2020 | 308 | 16.270 |
Why?
|
| Risk-Taking | 95 | 2020 | 435 | 13.950 |
Why?
|
| Unsafe Sex | 66 | 2018 | 161 | 13.550 |
Why?
|
| Substance-Related Disorders | 84 | 2021 | 685 | 12.630 |
Why?
|
| HIV Seropositivity | 56 | 2018 | 182 | 9.910 |
Why?
|
| Compulsive Behavior | 24 | 2023 | 30 | 7.750 |
Why?
|
| Condoms | 38 | 2020 | 132 | 7.160 |
Why?
|
| Adult | 225 | 2021 | 11034 | 7.080 |
Why?
|
| Male | 274 | 2023 | 18870 | 6.580 |
Why?
|
| New York City | 82 | 2019 | 212 | 6.090 |
Why?
|
| Young Adult | 125 | 2020 | 4012 | 5.980 |
Why?
|
| Internet | 26 | 2016 | 204 | 5.030 |
Why?
|
| Humans | 291 | 2023 | 34853 | 4.930 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2019 | 375 | 4.900 |
Why?
|
| Middle Aged | 126 | 2019 | 9642 | 4.470 |
Why?
|
| Medication Adherence | 19 | 2021 | 165 | 4.330 |
Why?
|
| Adolescent | 118 | 2020 | 5035 | 4.280 |
Why?
|
| Drug Users | 13 | 2019 | 42 | 3.980 |
Why?
|
| Anti-HIV Agents | 21 | 2021 | 394 | 3.960 |
Why?
|
| Risk Reduction Behavior | 18 | 2019 | 121 | 3.780 |
Why?
|
| Alcohol Drinking | 20 | 2020 | 490 | 3.540 |
Why?
|
| Safe Sex | 26 | 2019 | 73 | 3.530 |
Why?
|
| Depression | 23 | 2019 | 664 | 3.460 |
Why?
|
| Motivation | 30 | 2019 | 415 | 3.300 |
Why?
|
| Mental Health | 16 | 2017 | 270 | 3.170 |
Why?
|
| Stress, Psychological | 12 | 2017 | 541 | 2.740 |
Why?
|
| Social Support | 15 | 2017 | 356 | 2.570 |
Why?
|
| Counseling | 5 | 2019 | 105 | 2.430 |
Why?
|
| HIV Seronegativity | 10 | 2019 | 38 | 2.420 |
Why?
|
| Patient Compliance | 14 | 2017 | 202 | 2.390 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2018 | 165 | 2.370 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2018 | 63 | 2.340 |
Why?
|
| Attitude to Health | 14 | 2015 | 311 | 2.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 23 | 2019 | 790 | 2.250 |
Why?
|
| Methamphetamine | 10 | 2018 | 155 | 2.230 |
Why?
|
| Central Nervous System Stimulants | 10 | 2018 | 165 | 2.130 |
Why?
|
| Self Disclosure | 9 | 2017 | 42 | 2.110 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2023 | 13 | 2.080 |
Why?
|
| Female | 96 | 2021 | 19873 | 2.020 |
Why?
|
| Homosexuality | 8 | 2016 | 31 | 2.000 |
Why?
|
| Homosexuality, Female | 7 | 2012 | 55 | 1.970 |
Why?
|
| Interpersonal Relations | 16 | 2017 | 198 | 1.940 |
Why?
|
| Self Concept | 6 | 2019 | 136 | 1.850 |
Why?
|
| Emotions | 7 | 2018 | 204 | 1.840 |
Why?
|
| United States | 40 | 2020 | 3894 | 1.830 |
Why?
|
| Communication | 6 | 2019 | 170 | 1.820 |
Why?
|
| Aged | 45 | 2020 | 6448 | 1.780 |
Why?
|
| Anti-Retroviral Agents | 9 | 2021 | 139 | 1.750 |
Why?
|
| Patient Selection | 7 | 2018 | 154 | 1.740 |
Why?
|
| Social Behavior | 10 | 2015 | 124 | 1.730 |
Why?
|
| Stereotyping | 6 | 2013 | 40 | 1.730 |
Why?
|
| Mass Screening | 9 | 2019 | 427 | 1.690 |
Why?
|
| Viral Load | 15 | 2021 | 300 | 1.680 |
Why?
|
| Urban Population | 14 | 2016 | 318 | 1.670 |
Why?
|
| Socioeconomic Factors | 20 | 2016 | 1003 | 1.630 |
Why?
|
| Cross-Sectional Studies | 36 | 2018 | 2561 | 1.550 |
Why?
|
| Health Behavior | 10 | 2020 | 491 | 1.520 |
Why?
|
| Self Efficacy | 15 | 2021 | 173 | 1.520 |
Why?
|
| Psychometrics | 8 | 2018 | 292 | 1.510 |
Why?
|
| Prevalence | 23 | 2021 | 1425 | 1.500 |
Why?
|
| Longitudinal Studies | 14 | 2019 | 841 | 1.430 |
Why?
|
| Prescription Drugs | 3 | 2015 | 31 | 1.390 |
Why?
|
| Risk Factors | 31 | 2018 | 3414 | 1.380 |
Why?
|
| Minority Groups | 7 | 2017 | 537 | 1.380 |
Why?
|
| Child Abuse, Sexual | 4 | 2018 | 14 | 1.380 |
Why?
|
| Family Characteristics | 8 | 2019 | 102 | 1.370 |
Why?
|
| Decision Making | 4 | 2019 | 189 | 1.320 |
Why?
|
| Health Surveys | 15 | 2018 | 358 | 1.320 |
Why?
|
| Interviews as Topic | 15 | 2019 | 356 | 1.310 |
Why?
|
| Erotica | 2 | 2018 | 2 | 1.290 |
Why?
|
| Men | 4 | 2017 | 16 | 1.280 |
Why?
|
| Alcoholism | 8 | 2014 | 220 | 1.280 |
Why?
|
| Anxiety | 10 | 2019 | 705 | 1.260 |
Why?
|
| Social Identification | 5 | 2014 | 49 | 1.250 |
Why?
|
| Personal Satisfaction | 7 | 2019 | 56 | 1.230 |
Why?
|
| Data Collection | 14 | 2015 | 188 | 1.230 |
Why?
|
| Marijuana Smoking | 3 | 2019 | 82 | 1.220 |
Why?
|
| Behavior Therapy | 7 | 2010 | 145 | 1.210 |
Why?
|
| Gender Identity | 5 | 2017 | 93 | 1.160 |
Why?
|
| Spirituality | 2 | 2017 | 43 | 1.140 |
Why?
|
| Leisure Activities | 3 | 2011 | 31 | 1.120 |
Why?
|
| Object Attachment | 3 | 2019 | 24 | 1.120 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2019 | 185 | 1.100 |
Why?
|
| Cocaine-Related Disorders | 6 | 2014 | 84 | 1.070 |
Why?
|
| Alcohol-Related Disorders | 3 | 2012 | 52 | 1.050 |
Why?
|
| Executive Function | 2 | 2018 | 47 | 1.040 |
Why?
|
| Truth Disclosure | 6 | 2012 | 24 | 0.980 |
Why?
|
| Logistic Models | 15 | 2017 | 894 | 0.980 |
Why?
|
| Models, Psychological | 6 | 2017 | 120 | 0.970 |
Why?
|
| Research Personnel | 3 | 2016 | 133 | 0.960 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2010 | 219 | 0.950 |
Why?
|
| Pilot Projects | 12 | 2019 | 628 | 0.920 |
Why?
|
| Affect | 3 | 2015 | 147 | 0.910 |
Why?
|
| Health Promotion | 7 | 2018 | 588 | 0.900 |
Why?
|
| Disease Transmission, Infectious | 2 | 2015 | 29 | 0.900 |
Why?
|
| Social Environment | 6 | 2014 | 186 | 0.890 |
Why?
|
| Intention | 3 | 2018 | 84 | 0.850 |
Why?
|
| Transsexualism | 3 | 2011 | 17 | 0.850 |
Why?
|
| Hypnotics and Sedatives | 4 | 2015 | 27 | 0.840 |
Why?
|
| Personality Inventory | 4 | 2015 | 73 | 0.840 |
Why?
|
| Telemedicine | 4 | 2019 | 163 | 0.840 |
Why?
|
| AIDS Serodiagnosis | 5 | 2017 | 25 | 0.810 |
Why?
|
| Psychology | 3 | 2019 | 32 | 0.810 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 570 | 0.800 |
Why?
|
| Health Education | 5 | 2012 | 304 | 0.800 |
Why?
|
| Primary Prevention | 3 | 2016 | 57 | 0.780 |
Why?
|
| Comorbidity | 8 | 2019 | 606 | 0.750 |
Why?
|
| Mental Disorders | 2 | 2015 | 285 | 0.740 |
Why?
|
| Age Factors | 13 | 2019 | 1007 | 0.730 |
Why?
|
| Video Recording | 1 | 2019 | 32 | 0.720 |
Why?
|
| Home Care Services | 2 | 2017 | 29 | 0.720 |
Why?
|
| Patient Preference | 2 | 2018 | 46 | 0.720 |
Why?
|
| Military Personnel | 1 | 2020 | 67 | 0.710 |
Why?
|
| Qualitative Research | 8 | 2019 | 393 | 0.710 |
Why?
|
| Factor Analysis, Statistical | 6 | 2014 | 125 | 0.710 |
Why?
|
| Serologic Tests | 1 | 2019 | 43 | 0.700 |
Why?
|
| Depressive Disorder | 3 | 2017 | 166 | 0.690 |
Why?
|
| Residence Characteristics | 3 | 2016 | 301 | 0.690 |
Why?
|
| Program Evaluation | 5 | 2019 | 316 | 0.690 |
Why?
|
| Religion | 2 | 2017 | 77 | 0.680 |
Why?
|
| Cognition | 3 | 2021 | 373 | 0.670 |
Why?
|
| HIV-1 | 3 | 2010 | 678 | 0.650 |
Why?
|
| Prospective Studies | 6 | 2018 | 1353 | 0.650 |
Why?
|
| Harm Reduction | 4 | 2007 | 20 | 0.640 |
Why?
|
| Human Development | 1 | 2017 | 7 | 0.640 |
Why?
|
| Population Density | 1 | 2017 | 19 | 0.630 |
Why?
|
| San Francisco | 14 | 2006 | 33 | 0.620 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 901 | 0.620 |
Why?
|
| Religion and Sex | 1 | 2017 | 2 | 0.610 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 126 | 0.610 |
Why?
|
| Brazil | 4 | 2019 | 66 | 0.590 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 964 | 0.590 |
Why?
|
| Treatment Outcome | 12 | 2015 | 1349 | 0.580 |
Why?
|
| Urethral Diseases | 1 | 2016 | 1 | 0.570 |
Why?
|
| Sex Factors | 10 | 2016 | 859 | 0.570 |
Why?
|
| Rectal Diseases | 1 | 2016 | 4 | 0.570 |
Why?
|
| Crime Victims | 1 | 2016 | 69 | 0.560 |
Why?
|
| Gonorrhea | 1 | 2016 | 31 | 0.540 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2333 | 0.540 |
Why?
|
| Men's Health | 2 | 2012 | 9 | 0.530 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 14 | 0.530 |
Why?
|
| Sex Education | 4 | 2014 | 29 | 0.530 |
Why?
|
| Perception | 6 | 2018 | 183 | 0.520 |
Why?
|
| Chlamydia Infections | 2 | 2018 | 196 | 0.510 |
Why?
|
| Self Care | 2 | 2013 | 150 | 0.510 |
Why?
|
| Disclosure | 2 | 2004 | 31 | 0.500 |
Why?
|
| Penis | 2 | 2012 | 72 | 0.490 |
Why?
|
| Voluntary Programs | 1 | 2014 | 4 | 0.490 |
Why?
|
| Culture | 5 | 2014 | 162 | 0.490 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2005 | 123 | 0.480 |
Why?
|
| Cohort Studies | 5 | 2018 | 1422 | 0.470 |
Why?
|
| New York | 7 | 2013 | 69 | 0.470 |
Why?
|
| Heterosexuality | 1 | 2014 | 85 | 0.460 |
Why?
|
| Group Processes | 1 | 2013 | 21 | 0.460 |
Why?
|
| Preventive Health Services | 1 | 2013 | 61 | 0.460 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 207 | 0.460 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 628 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2018 | 214 | 0.460 |
Why?
|
| Antisocial Personality Disorder | 1 | 2013 | 17 | 0.460 |
Why?
|
| Quality of Life | 1 | 2017 | 459 | 0.460 |
Why?
|
| Love | 1 | 2012 | 6 | 0.440 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 358 | 0.440 |
Why?
|
| Adult Survivors of Child Abuse | 3 | 2018 | 20 | 0.430 |
Why?
|
| Femininity | 1 | 2012 | 5 | 0.430 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 531 | 0.430 |
Why?
|
| Masculinity | 1 | 2012 | 15 | 0.420 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 446 | 0.420 |
Why?
|
| Health Status Disparities | 2 | 2017 | 583 | 0.410 |
Why?
|
| Hobbies | 1 | 2011 | 2 | 0.410 |
Why?
|
| Negotiating | 4 | 2016 | 26 | 0.400 |
Why?
|
| Program Development | 4 | 2016 | 225 | 0.400 |
Why?
|
| Science | 1 | 2011 | 17 | 0.400 |
Why?
|
| Risk Management | 1 | 2010 | 8 | 0.390 |
Why?
|
| Sampling Studies | 3 | 2016 | 60 | 0.390 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 243 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 233 | 0.390 |
Why?
|
| Time Factors | 6 | 2015 | 1681 | 0.390 |
Why?
|
| Religion and Psychology | 1 | 2010 | 25 | 0.380 |
Why?
|
| Sexuality | 2 | 2011 | 50 | 0.380 |
Why?
|
| Models, Theoretical | 4 | 2017 | 210 | 0.380 |
Why?
|
| Focus Groups | 6 | 2016 | 307 | 0.370 |
Why?
|
| Alcoholic Intoxication | 1 | 2010 | 20 | 0.370 |
Why?
|
| Los Angeles | 6 | 2018 | 368 | 0.370 |
Why?
|
| Regression Analysis | 6 | 2018 | 429 | 0.360 |
Why?
|
| Psychotherapy, Group | 1 | 2009 | 18 | 0.360 |
Why?
|
| Interview, Psychological | 1 | 2009 | 58 | 0.350 |
Why?
|
| Syphilis | 1 | 2009 | 27 | 0.350 |
Why?
|
| Smoking | 3 | 2012 | 903 | 0.350 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 45 | 0.350 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 27 | 0.350 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2019 | 8 | 0.350 |
Why?
|
| Feasibility Studies | 6 | 2019 | 196 | 0.340 |
Why?
|
| Analysis of Variance | 4 | 2014 | 528 | 0.340 |
Why?
|
| Research Design | 5 | 2018 | 292 | 0.330 |
Why?
|
| Family | 1 | 2009 | 162 | 0.330 |
Why?
|
| Clinical Competence | 1 | 2009 | 124 | 0.330 |
Why?
|
| Risk Assessment | 8 | 2018 | 727 | 0.310 |
Why?
|
| Psychotherapy | 2 | 2023 | 43 | 0.310 |
Why?
|
| Awareness | 2 | 2018 | 59 | 0.310 |
Why?
|
| Drug Prescriptions | 2 | 2007 | 42 | 0.310 |
Why?
|
| Sleep | 2 | 2019 | 122 | 0.310 |
Why?
|
| Thailand | 5 | 2014 | 48 | 0.300 |
Why?
|
| Spouse Abuse | 1 | 2007 | 43 | 0.290 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2012 | 343 | 0.290 |
Why?
|
| Life Change Events | 1 | 2007 | 85 | 0.290 |
Why?
|
| Needs Assessment | 1 | 2007 | 159 | 0.270 |
Why?
|
| Health Personnel | 2 | 2018 | 200 | 0.270 |
Why?
|
| Loneliness | 2 | 2019 | 8 | 0.270 |
Why?
|
| Impulsive Behavior | 2 | 2016 | 44 | 0.260 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 213 | 0.250 |
Why?
|
| Lysergic Acid Diethylamide | 3 | 2009 | 4 | 0.250 |
Why?
|
| Body Image | 2 | 2017 | 68 | 0.250 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2009 | 8 | 0.250 |
Why?
|
| Ketamine | 3 | 2009 | 11 | 0.250 |
Why?
|
| Prejudice | 3 | 2012 | 101 | 0.240 |
Why?
|
| Life Style | 1 | 2006 | 288 | 0.240 |
Why?
|
| Demography | 3 | 2009 | 167 | 0.240 |
Why?
|
| Terrorism | 1 | 2003 | 12 | 0.230 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 22 | 0.230 |
Why?
|
| Social Class | 2 | 2016 | 228 | 0.220 |
Why?
|
| Health Status | 5 | 2017 | 356 | 0.220 |
Why?
|
| Antiviral Agents | 2 | 2016 | 148 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2014 | 171 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2014 | 517 | 0.200 |
Why?
|
| Retrospective Studies | 2 | 2019 | 1961 | 0.200 |
Why?
|
| Child | 5 | 2023 | 2875 | 0.200 |
Why?
|
| Adolescent Behavior | 5 | 2016 | 243 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 61 | 0.190 |
Why?
|
| Injections | 2 | 2018 | 35 | 0.190 |
Why?
|
| HIV Long-Term Survivors | 2 | 2010 | 6 | 0.180 |
Why?
|
| Space-Time Clustering | 2 | 2009 | 3 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2019 | 17 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 176 | 0.180 |
Why?
|
| Social Perception | 3 | 2013 | 59 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2012 | 213 | 0.170 |
Why?
|
| Hallucinogens | 2 | 2009 | 25 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 22 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2019 | 110 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 47 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2018 | 44 | 0.170 |
Why?
|
| Shame | 1 | 2018 | 3 | 0.170 |
Why?
|
| Sodium Oxybate | 2 | 2009 | 2 | 0.170 |
Why?
|
| HIV | 1 | 2018 | 97 | 0.160 |
Why?
|
| Choice Behavior | 3 | 2007 | 75 | 0.160 |
Why?
|
| Defense Mechanisms | 1 | 2017 | 9 | 0.160 |
Why?
|
| Fatigue | 1 | 2018 | 79 | 0.160 |
Why?
|
| Probability | 1 | 2018 | 75 | 0.160 |
Why?
|
| Puberty | 1 | 2017 | 25 | 0.160 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 141 | 0.150 |
Why?
|
| Risk | 2 | 2016 | 256 | 0.150 |
Why?
|
| Minority Health | 1 | 2017 | 81 | 0.140 |
Why?
|
| Multilevel Analysis | 1 | 2015 | 16 | 0.140 |
Why?
|
| Language | 2 | 2014 | 143 | 0.140 |
Why?
|
| Rural Population | 1 | 2017 | 253 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 75 | 0.130 |
Why?
|
| Sex Offenses | 1 | 2015 | 33 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 94 | 0.130 |
Why?
|
| Personality Disorders | 1 | 2014 | 9 | 0.130 |
Why?
|
| Translating | 1 | 2014 | 16 | 0.130 |
Why?
|
| Cultural Characteristics | 2 | 2012 | 119 | 0.130 |
Why?
|
| Social Facilitation | 1 | 2014 | 5 | 0.130 |
Why?
|
| Analgesics | 1 | 2015 | 56 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 186 | 0.130 |
Why?
|
| Domestic Violence | 1 | 2014 | 24 | 0.130 |
Why?
|
| Linear Models | 2 | 2013 | 253 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 424 | 0.130 |
Why?
|
| Uncertainty | 2 | 2011 | 25 | 0.130 |
Why?
|
| Organ Size | 2 | 2012 | 148 | 0.130 |
Why?
|
| Personality | 1 | 2014 | 36 | 0.130 |
Why?
|
| Social Responsibility | 2 | 2004 | 12 | 0.130 |
Why?
|
| Incidence | 2 | 2010 | 882 | 0.120 |
Why?
|
| Random Allocation | 1 | 2014 | 139 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2013 | 13 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2013 | 89 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2013 | 188 | 0.120 |
Why?
|
| Utilization Review | 1 | 2013 | 14 | 0.120 |
Why?
|
| Consumer Health Information | 1 | 2013 | 22 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 13 | 0.120 |
Why?
|
| Urban Health | 1 | 2013 | 86 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 32 | 0.120 |
Why?
|
| Psychopathology | 1 | 2013 | 14 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2013 | 39 | 0.110 |
Why?
|
| Jealousy | 1 | 2012 | 2 | 0.110 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 83 | 0.110 |
Why?
|
| Cannabinoids | 1 | 2013 | 54 | 0.110 |
Why?
|
| Caffeine | 1 | 2012 | 26 | 0.110 |
Why?
|
| Internal-External Control | 2 | 2009 | 47 | 0.110 |
Why?
|
| Educational Status | 1 | 2013 | 295 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 106 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 608 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2017 | 283 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 55 | 0.100 |
Why?
|
| Psychological Tests | 2 | 2013 | 52 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 239 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 255 | 0.100 |
Why?
|
| Observation | 1 | 2011 | 8 | 0.100 |
Why?
|
| Birds | 1 | 2011 | 30 | 0.100 |
Why?
|
| New Jersey | 1 | 2010 | 15 | 0.100 |
Why?
|
| Psychological Theory | 2 | 2009 | 23 | 0.100 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2009 | 1 | 0.090 |
Why?
|
| Recreation | 1 | 2010 | 29 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 600 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 41 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 92 | 0.090 |
Why?
|
| Public Health | 1 | 2013 | 348 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2009 | 111 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 44 | 0.090 |
Why?
|
| Inservice Training | 1 | 2009 | 30 | 0.090 |
Why?
|
| Social Isolation | 2 | 2010 | 27 | 0.090 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 7 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 142 | 0.090 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2009 | 75 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 20 | 0.080 |
Why?
|
| Anecdotes as Topic | 2 | 2008 | 5 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2009 | 212 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 781 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 171 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2012 | 1318 | 0.080 |
Why?
|
| Fear | 2 | 2015 | 234 | 0.080 |
Why?
|
| Health Literacy | 1 | 2009 | 100 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 195 | 0.080 |
Why?
|
| Peer Group | 2 | 2005 | 138 | 0.080 |
Why?
|
| Citalopram | 1 | 2006 | 2 | 0.080 |
Why?
|
| Cocaine | 1 | 2009 | 219 | 0.080 |
Why?
|
| Goals | 1 | 2007 | 30 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 28 | 0.070 |
Why?
|
| Breast Self-Examination | 1 | 2006 | 10 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2006 | 17 | 0.070 |
Why?
|
| Ejaculation | 1 | 2005 | 11 | 0.070 |
Why?
|
| Women's Health | 1 | 2006 | 135 | 0.070 |
Why?
|
| Piperazines | 1 | 2005 | 109 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 322 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 642 | 0.060 |
Why?
|
| Self Administration | 1 | 2003 | 41 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2003 | 143 | 0.050 |
Why?
|
| Telephone | 1 | 2020 | 32 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 90 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 8 | 0.050 |
Why?
|
| Chlamydia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Animals | 2 | 2013 | 14307 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 58 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 212 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 299 | 0.040 |
Why?
|
| Confidentiality | 1 | 2016 | 26 | 0.040 |
Why?
|
| Social Conditions | 1 | 2015 | 12 | 0.030 |
Why?
|
| California | 2 | 2010 | 436 | 0.030 |
Why?
|
| Patient Participation | 2 | 2006 | 68 | 0.030 |
Why?
|
| Anthropology, Cultural | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hierarchy, Social | 1 | 2014 | 9 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 6 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 43 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 15 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 87 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 114 | 0.030 |
Why?
|
| Computers | 1 | 2013 | 27 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 143 | 0.030 |
Why?
|
| Tennessee | 1 | 2013 | 59 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 49 | 0.030 |
Why?
|
| North Carolina | 1 | 2013 | 103 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 298 | 0.030 |
Why?
|
| Florida | 1 | 2013 | 358 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 100 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 200 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 195 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 205 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 151 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 1023 | 0.020 |
Why?
|
| Compulsive Personality Disorder | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 142 | 0.020 |
Why?
|
| Students | 1 | 2012 | 452 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2007 | 44 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2128 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2006 | 269 | 0.020 |
Why?
|
| Informed Consent | 1 | 2006 | 30 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 30 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 30 | 0.020 |
Why?
|
| Purines | 1 | 2005 | 37 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 26 | 0.020 |
Why?
|
| Sulfones | 1 | 2005 | 40 | 0.020 |
Why?
|
| Narration | 1 | 2005 | 27 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 53 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 137 | 0.020 |
Why?
|
| Testosterone | 1 | 2005 | 181 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 5668 | 0.010 |
Why?
|